These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 3423522)
1. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene]. Cremer P; Vekemans M Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522 [No Abstract] [Full Text] [Related]
2. Comparative study on the acceptability of two modern monophasic oral contraceptive preparations: 30 microgram ethinyl estradiol combined with 150 microgram desogestrel or 75 microgram gestodene. Zichella L; Sbrignadello C; Tomassini A; Di Lieto A; Montoneri C; Zarbo G; Mancone M; Pietrobattista P; Bertoli G; Perrone G Adv Contracept; 1999; 15(3):191-200. PubMed ID: 11019950 [TBL] [Abstract][Full Text] [Related]
3. Body weight change during use of a monophasic oral contraceptive containing 20 microg ethinylestradiol and 75 microg gestodene with a comparison of the women who completed versus those who prematurely discontinued intake. Endrikat J; Gerlinger C; Cronin M; Wessel J; Ruebig A; Rosenbaum P; Düsterberg B Eur J Contracept Reprod Health Care; 2001 Dec; 6(4):199-204. PubMed ID: 11848649 [TBL] [Abstract][Full Text] [Related]
4. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles]. Bilotta P; Favilli S Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705 [No Abstract] [Full Text] [Related]
5. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781 [TBL] [Abstract][Full Text] [Related]
6. [Side effects of oral contraceptives in the first treatment cycle]. Feichtinger W; Babor P; Herczeg KM; Heyda M; Hoffmann R; Plöckinger B; Steinhauser B Wien Med Wochenschr; 1991; 141(18-19):412-5. PubMed ID: 1837965 [TBL] [Abstract][Full Text] [Related]
8. Use of an oral contraceptive containing drospirenone in an extended regimen. Sillem M; Schneidereit R; Heithecker R; Mueck AO Eur J Contracept Reprod Health Care; 2003 Sep; 8(3):162-9. PubMed ID: 14667328 [TBL] [Abstract][Full Text] [Related]
9. Investigation of the influence of two low-dose monophasic oral contraceptives containing 20 micrograms ethinylestradiol/75 micrograms gestodene and 30 micrograms ethinylestradiol/75 micrograms gestodene, on lipid metabolism in an open randomized trial. Brill K; Then A; Beisiegel U; Jene A; Wünsch C; Leidenberger F Contraception; 1996 Nov; 54(5):291-7. PubMed ID: 8934063 [TBL] [Abstract][Full Text] [Related]
10. [Clinical study of a low-dose contraceptive--Femodene]. Rachev E; Damianov L; Dukovski A; Katsarova M Akush Ginekol (Sofiia); 1995; 34(3):71-3. PubMed ID: 8787249 [TBL] [Abstract][Full Text] [Related]
11. Effects of two oral contraceptives, containing 30 or 20 microg of ethinyl estradiol in combination with gestodene, on blood coagulation and fibrinolysis in Brazilian women. Ferreira AC; Montes MB; Franceschini SA; Toloi MR Int J Fertil Womens Med; 2001; 46(5):265-70. PubMed ID: 11720199 [TBL] [Abstract][Full Text] [Related]
12. Oral contraceptives according to the normophasic principle. Borglin NE; Klottrup P Arzneimittelforschung; 1978; 28(12):2354-7. PubMed ID: 582954 [TBL] [Abstract][Full Text] [Related]
13. [Effects of oral estrogen-progestin contraceptives on blood coagulation and assessment of the risk of thromboembolism]. Surico N; Porcelli A; Petrelli P; Amedeo M; Crivello T; Ferraris G Minerva Ginecol; 1988 Sep; 40(9):559-62. PubMed ID: 2975773 [No Abstract] [Full Text] [Related]
14. Cycle control, safety and acceptability of a new oral contraceptive containing ethinylestradiol 15 micrograms and gestodene 60 micrograms. Jaithitivit L; Jaisamrarn U; Taneepanichskul S J Med Assoc Thai; 2012 May; 95(5):630-5. PubMed ID: 22994020 [TBL] [Abstract][Full Text] [Related]
15. Serum resistin levels in women taking combined oral contraceptives containing desogestrel or gestodene. Rechberger T; Tomaszewski J; Pieprzowska-Białek A; Kulik-Rechberger B; Skorupski P Contraception; 2004 Jun; 69(6):477-80. PubMed ID: 15157792 [TBL] [Abstract][Full Text] [Related]
16. Toward a new concept of "natural balance" in oral estroprogestin contraception. Chabbert-Buffet N; Gerris J; Jamin C; Lello S; Lete I; Lobo P; Nappi RE; Pintiaux A Gynecol Endocrinol; 2013 Oct; 29(10):891-6. PubMed ID: 23931030 [TBL] [Abstract][Full Text] [Related]
17. Effect of a low-dose ethinylestradiol and gestodene in combination on the frequency of micronuclei in human peripheral blood lymphocytes of healthy women in vivo. Loncar D; Milosević-Djordjević O; Zivanović A; Grujicić D; Arsenijević S Contraception; 2004 Apr; 69(4):327-31. PubMed ID: 15033409 [TBL] [Abstract][Full Text] [Related]
19. [Our experience with the use of the contraceptive preparations Femovan and Triquilar from the Schering firm]. Milchev N; Terzhumanov R; Grozdanov G; Krumov G Akush Ginekol (Sofiia); 1992; 31(2):42-3. PubMed ID: 1342561 [No Abstract] [Full Text] [Related]
20. [The effectiveness and acceptability of oral contraceptives (Logest), containing 20 micrograms ethinylestradiol and 75 micrograms gestodene]. Lech MM; Swiatek EJ Ginekol Pol; 2004 Mar; 75(3):209-14. PubMed ID: 15181879 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]